Alcohol Dependence Clinical Trial
Official title:
Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study
The main aim of this research is to investigate whether the use of cognitive event-related
potentials is an interesting way to identify subgroups of alcoholic patients displaying
specific clinical symptoms and cognitive disturbances in order to help clinicians to adapt
the pharmaceutical approach to the specific needs of the patient.
Nowadays, a fundamental question remains: How can investigators identify among alcoholic
patients who are likely to benefit from the use of naltrexone, acamprosate or baclofen, and
those who are not? The goal of this application is to identify subgroups of alcoholic
patients displaying specific clinical symptoms and cognitive disturbances linked to
consistent biological markers. Investigators propose that this might help clinicians improve
their treatment of alcoholic patients by focusing therapy on individual cognitive
disturbances, and by adapting pharmaceutical approaches to the identified brain
pathophysiology. In other words, investigators suggest that specifying the cognitive profile
of each individual patient may help clinicians in their choice of a suitable drug program.
To reach this aim, investigators suggest that a joined investigation of early (P100) and late
(P300) brain event-related potentials (ERP) components may help create subgroups of alcoholic
patients with homogenous cognitive deficits, and that this ''classification'' might help
optimize drug treatment. More precisely, investigators suggest that relapse in chronic
alcoholism is partly due to (1) the preferential attentional allocation to alcohol-related
information (e.g. the sight of a bottle of wine). As the P100 component has already been
shown to be enhanced by motivationally relevant stimuli, investigators think that this
component is well-suited for this purpose; and (2) the impairment of the inhibitory control,
which is necessary to suppress an inappropriate prepotent response. The Go/No-Go task is a
simple procedure, which has already proven to be highly reliable to evidence a deficit in
inhibitory control processing in alcoholics, indexed by a No-Go P3 of decreased amplitude and
less anterior topography. In summary, investigators have two simple experimental procedures,
an oddball task and a Go/No-Go task, which can be easily carried out in clinical settings,
and which can provide interesting data concerning, respectively, the existence of an implicit
attentional bias towards alcohol-cues and the deficit of inhibitory control towards a
prepotent response, through the observation of well-known and well-described cognitive ERP
components, i.e. the P100 and P3b components. The main goal of this project will be to test
the effect of different drug medications on both attentional (P100) and inhibitory (P300)
deficits observable in alcoholic patients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |